This brand name is authorized in Japan, Lithuania.
The drug GRANDAXIN contains one active pharmaceutical ingredient (API):
1
|
UNII
UZC80HAU42 - TOFISOPAM
|
|
Tofisopam is an atypical benzodiazepine derivative. It has an anxiolytic effect, almost not-accompanied by a sedative, muscle relaxant, anticonvulsant action. Tofisopam is a psychovegetative regulator, it eliminates various forms of autonomic disorders. It has a mild stimulating activity. Due to the lack miorelaxant effect tofisopam can also be used in patients with myopathy and myasthenia. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| N05BA23 | Tofisopam | N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BA Benzodiazepine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| JP | 医薬品医療機器総合機構 | 1124026F1022 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1007131 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.